ImageneBio (NASDAQ: IMA) registers 2,508,337 resale shares

Rhea-AI Filing Summary

ImageneBio, Inc. files a prospectus supplement to register 2,508,337 shares of Common Stock for offer and resale by identified selling stockholders. The supplement updates the April 2, 2026 prospectus with selected Form 10-Q information and notes a last reported sale price of $6.08 per share on May 6, 2026.

The registration relates to resale or other dispositions "from time to time by the selling stockholders" under Registration No. 333-290108; the supplement is dated May 7, 2026 and references the Prospectus dated April 2, 2026.

Key Figures

Registered shares: 2,508,337 shares Last reported sale price: $6.08 Registration number: 333-290108

3 metrics

Registered shares 2,508,337 shares offered for resale by selling stockholders

Last reported sale price $6.08 per share, reported on May 6, 2026

Registration number 333-290108 registration statement on Form S-1

Key Terms

prospectus supplement, selling stockholders, registration statement on Form S-1

3 terms

prospectus supplement regulatory

"This prospectus supplement supplements the prospectus dated April 2, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

selling stockholders financial

"resale or other disposition from time to time by the selling stockholders identified in this prospectus"

Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.

registration statement on Form S-1 regulatory

"registration statement on Form S-1 (No. 333-290108), as amended"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

Offering Details

resale/secondary

Offering

Offering Type resale/secondary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 08:48 PM Learn about SEC filing dates

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-290108

PROSPECTUS SUPPLEMENT

(To Prospectus dated April 2, 2026)

ImageneBio, Inc.

2,508,337 Shares of Common Stock

This prospectus supplement supplements the prospectus dated April 2, 2026 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-290108), as amended. This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 7, 2026 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report in relevant part to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in this prospectus of 2,508,337 shares of common stock, par value $0.001 per share, (the “Common Stock”) of ImageneBio, Inc.

Our Common Stock is listed on the Nasdaq Capital Market under the ticker symbol “IMA.” On May 6, 2026, the last reported sales price of our Common Stock was $6.08 per share.

This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements to it, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information provided by this prospectus supplement supersedes information contained in the Prospectus.

This prospectus supplement is not complete without, and may not be delivered or used except in conjunction with, the Prospectus, including any amendments or supplements to it.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 6 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is May 7, 2026